Publicacions
-
Fernandez-Sojo J, Horton R, Cid J, Azqueta C, Garcia-Buendia A, Valdivia E, Martorell L, Rubio-Lopez N, Codinach M, Aran G, Marsal-Ricoma J, Mussetti A, Martino R, Diaz-de-Heredia C, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia-Rey E, García-Muñoz N, Medina L, Carreras E, Villa J, Lozano M, Gibson D and Querol S.
Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry
BONE MARROW TRANSPLANTATION . 57(10): 1531-1538. Nº de cites: 3
-
Ortigoza-Escobar JD, Fernández de Sevilla-Estrach M, Monfort L, Anton-Lopez J, Iglesias-Jimenez E, Rebollo M, Cristina Del prado Sanchez, Arostegui JI, Mensa-Vilaró A, Alsina L, Rodriguez-Vigil Iturrate C, Niemeyer CM, Jou-Munoz C and Català-Temprano A.
Cytokine profile and brain biopsy in a case of childhood-onset central nervous system vasculitis in Noonan syndrome-like disorder due to a novel CBL variant
JOURNAL OF NEUROIMMUNOLOGY . 369: 577917-577917.
-
Ramos-Muntada M, Trincado JL, Blanco J, Bueno C, Rodríguez-Cortez VC, Bataller A, López-Millán B, Schwab C, Ortega M, Velasco P, Blanco ML, Nomdedeu J, Ramírez-Orellana M, Minguela A, Fuster JL, Cuatrecasas E, Camós-Guijosa M, Ballerini P, Escherich G, Boer J, denBoer M, Hernández-Rivas JM, Calasanz MJ, Cazzaniga G, Harrison CJ, Menéndez P and Molina O.
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
MOLECULAR ONCOLOGY . 16(16): 2899-2919. Nº de cites: 2
-
Kobialka P, Sabata H, Vilalta O, Gouveia L, Angulo-Urarte A, Muixí L, Zanoncello J, Muñoz-Aznar O, Gene-Olaciregui N, Fanlo L, Esteve-Codina A, Lavarino C, Javierre BM, Celis-Passini V, Rovira-Zurriaga C, López-Fernández S, Baselga E, Mora J, Castillo SD and Graupera M.
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib
EMBO Molecular Medicine . 14(7): . Nº de cites: 15
-
Bueno C, Barrena S, Bataller A, Ortiz-Maldonado V, Elliott N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, Gonzalez M, Morgades M, Sorigué M, Barcena P, Zanetti SR, Torrebadell-Burriel M, Vega-García N, Rives-Solà S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan-Otero M, Delgado J, Urbano-Ispizua Á, Ribera JM, Orfao A, Roy A and Menéndez P.
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
Blood . 140(1): 38-44. Nº de cites: 14
-
García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.
MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
BMC Cancer . 22(1): 669-669. Nº de cites: 8
-
Megías-Vericat JE, Bonanad Boix S, Berrueco R, Mingot-Castellano ME, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas JM, Haya Guaita S, Mesegue-Meda M, López Jaime F, Albo-López C, Palomero-Massanet A, Vilalta Seto N, Leciñena IL, Haro ARC and Poveda Andrés JL.
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
THROMBOSIS RESEARCH . 216: 35-42. Nº de cites: 4
-
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives-Solà S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F and Zwaan CM.
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Leukemia . 36(6): 1516-1524. Nº de cites: 17
-
Laetsch TW, Maude SL, Balduzzi A, Rives-Solà S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R and Grupp SA.
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
Leukemia . 36(6): 1508-1515. Nº de cites: 15
-
Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català-Temprano A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell-Burriel M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan-Otero M, Delgado J and Rives-Solà S.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease
AMERICAN JOURNAL OF HEMATOLOGY . 97(6): 731-739. Nº de cites: 2